Science Immunology
Supplementary Materials
The PDF file includes:
- Materials and Methods
- Table S1. List of antibodies used for flow cytometry and immunohistochemistry examination.
- Table S2. Pharmacokinetic profiles of the antibody nanoparticles.
- Fig. S1. Synthetic route for MMP-2–liable PEG-PLGLAG-dEGCG.
- Fig. S2. Electrospray ionization (ESI) mass spectrum of the dimer of EGCG (dEGCG).
- Fig. S3. Matrix-assisted laser desorption/ionization–time-of-flight (MALDI-TOF) mass spectra of EGCG conjugates.
- Fig. S4. HPLC examination of MMP-2–mediated degradation of the PLGLAG spacer.
- Fig. S5. MALDI-TOF mass spectra of MMP-2–insensitive PEGylated EGCG.
- Fig. S6. Characterization of S-αPDL1/ICG@NP assembly process.
- Fig. S7. Representative TEM image of the S-αPDL1/ICG@NP.
- Fig. S8. Serum stability of S-αPDL1/ICG@NP.
- Fig. S9. PDL1 binding affinity of αPDL1 in S-αPDL1/ICG@NP post PDT.
- Fig. S10. ESR spectroscopic examination of S-αPDL1/ICG@NP–induced ROS.
- Fig. S11. S-αPDL1/ICG@NP induced ROS generation and phototoxicity in vitro.
- Fig. S12. Flow cytometric examination of PDL1 expression in different cell lines.
- Fig. S13. Intracellular uptake property of S-αPDL1/ICG@NP.
- Fig. S14. Pharmacokinetic profiles of nanoparticles in vivo.
- Fig. S15. Fluorescence imaging of 4T1 tumors at desired time after different treatments.
- Fig. S16. Immunohistochemical examination of MMP-2 expression.
- Fig. S17. Quantification of αPDL1 distribution in major organs.
- Fig. S18. Normalized tumoral infiltration of CD3+ and CD4+ T cells in control and treated groups.
- Fig. S19. The tumor growth plots of 4T1 tumor–bearing mice in control and treated groups.
- Fig. S20. Body weight change recorded during the experimental period.
- Fig. S21. H&E staining of the normal organs examined at the end of the antitumor study.
- Fig. S22. TUNEL analysis of S-αPDL1/ICG@NP–mediated antitumor effects.
- Fig. S23. H&E staining of the lung sections at the end of the antitumor study.
- Fig. S24. Relative growth curves of B16-F10 tumors after various treatments.
- Fig. S25. Survival curves of B16-F10 tumors in control and treated groups.
Other Supplementary Material for this manuscript includes the following:
Files in this Data Supplement: